| Maternal and Child Outcomes Associated with the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)
(Systematic Review, released on April 19, 2022) The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) aims to safeguard the health of low-income, nutritionally at-risk pregnant and postpartum women and children less than 5 years old. This systematic review evaluates whether participation in WIC is associated with nutrition and health outcomes for women, infants, and children, and whether the associations vary by duration of participation or across subgroups. The Effective Health Care (EHC) Program is interested in receiving supplemental evidence and data (SEADs) for systematic reviews that are relevant to the questions in our evidence reports. To ensure that it has full access to relevant research, whether or not it is published, the EHC Program is interested in receiving SEADs containing detailed study-specific information. Opportunities to submit scientific information are available for: Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update
(Available for submission until May 16, 2022) The purpose of this review is to integrate new evidence that can update the prior review on medical treatment for alcohol-use disorders with the goal of providing current data that are of use in decision making to guideline developers, clinicians, and patients. Postpartum Home Blood Pressure Monitoring, Postpartum Treatment of Hypertensive Disorders of Pregnancy, and Peripartum Magnesium Sulfate Regimens for Preeclampsia with Severe Features
(Submission deadline extended until April 28, 2022) The purpose of the review is to summarize the findings from (1) studies of home BP monitoring in the postpartum period, (2) studies of pharmacological treatment of HDP in the postpartum period, and (3) studies comparing the effectiveness and harms of different MgSO4 regimens in patients with preeclampsia with severe features to prevent eclampsia during the peripartum period. For the third topic, the peripartum period is operationally defined as the time interval prior to, during, or after delivery when individuals may be diagnosed with preeclampsia with severe features. For all topics, the review will summarize findings related to differences in treatment effectiveness (and harms) in different populations, with an emphasis, as feasible, on factors related to healthcare disparities and pregnancy-related risk factors.
(Section 944 (c) of the Public Health Service Act [42 U.S.C. 299c 3(c)] requires that information collected for research conducted or supported by AHRQ that identifies individuals or establishments be used only for the purpose for which it was supplied unless they consent to the use of the information for another purpose.)
About us: AHRQ's Effective Health Care Program is committed to providing the best available evidence on the outcomes, benefits and harms, and appropriateness of drugs, devices, and health care services and by helping health care professionals, patients, policymakers, and health care systems make informed health care decisions. The program partners with research centers, academic institutions, health professional societies, consumer organizations, and other stakeholders to conduct research, evidence synthesis, evidence translation, dissemination, and implementation of research findings. To learn more: https://effectivehealthcare.ahrq.gov/ Contact us at epc@ahrq.hhs.gov | 
How satisfied are you with this e-mail bulletin? Give Us Your Feedback
No comments:
Post a Comment